|Principal Investigator: JulieShakib|
|Keywords: Stannsoporfin , Pediatrics , Hyperbilirubinemia||Department: Pediatric Administration|
|IRB Number: 00066249||Co Investigator: Michael Spigarelli|
|Specialty: Pediatrics, General|
The objectives of this follow up study are to evaluate the long-term effects of stannsoporfin (Stanate) on the health, growth, and development of patients who received a single dose of stannsoporfin with PT used to treat hyperbilirubinemia compared with patients in the control (placebo plus PT) group in clinical trial 64,185-204.
Patients will meet the following entry criteria for study eligibility:
• Patients who have received IMP (stannsoporfin or placebo) in clinical trial 64,185-204
• Written informed consent provided by parents/guardians